Details for New Drug Application (NDA): 062648
✉ Email this page to a colleague
NDA 062648 describes ERYC 125, which is a drug marketed by Parke Davis and is included in one NDA. Additional details are available on the ERYC 125 profile page.
The generic ingredient in ERYC 125 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
The generic ingredient in ERYC 125 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Summary for 062648
| Tradename: | ERYC 125 |
| Applicant: | Parke Davis |
| Ingredient: | erythromycin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062648
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | 125MG | ||||
| Approval Date: | Oct 24, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
